楊培銘(Yang, Pei-Ming) 副教授

Email
yangpm@tmu.edu.tw
現   職
癌症生物學與藥物研發研究所 副教授

學經歷

學 歷

畢業學校與學位[修業時間]
國立清華大學生命科學系 博士
2000/09/01~2006/06/01
國立清華大學生命科學系 學士
1996/09/01~2000/06/01

本校學術經歷

任職單位與職稱[起迄時間]
癌症生物學與藥物研發研究所副教授
2018/12/01~
癌症生物學與藥物研發博士學位學程副教授
2016/11/01~2018/11/30
癌症生物學與藥物研發博士學位學程副教授
2016/02/01~2016/10/31
癌症生物學與藥物研發博士學位學程助理教授
2012/10/01~2016/01/31
癌症生物學與藥物研發博士學位學程助理研究員
2012/09/03~2012/09/30

本校行政經歷

服務單位與職稱[起迄時間]
癌症生物學與藥物研發博士學位學程副教授
2019/01/01 ~

其它經歷

任職單位與職稱[起迄時間]
台大醫學院藥理所助理研究學者
2012/08/01~2012/08/31
台大醫學院藥理所台灣大學邁向頂尖大學計劃博士後研究員
2012/01/01~2012/07/31
台大醫學院藥理所特約博士後研究學者
2010/01/01~2011/12/31
台大醫學院藥理所博士後研究
2007/11/12~2009/12/31

專長與研究領域

學門領域
生物學之生化及分子生物
藥理及毒理
醫學之生化及分子生物
學術專長
Western blotting

論文著作

清冊下載


1. 2020 Yang PM,Lin LS,Liu TP. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. . Biomolecules .2020 ;(10):117-117

2. 2020 Chen CH,Hsieh YC,Yang PM,Liu YR,Cho EC. Dicoumarol suppresses HMGA2-mediated oncogenic capacities and inhibits cell proliferation by inducing apoptosis in colon cancer. . Biochemical and Biophysical Research Communications .2020 ;(524):1003-1009

3. 2019 Hsieh YY,Liu TP,Yang PM. In silico repurposing the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing clear cell renal carcinoma . Pathology-Research and Practice .2019 ;(215):152373

4. 2019 Chen JC,Hsieh YY,Lo HL,Li A,Chou CJ,Yang PM. In vitro and in silico mechanistic insights into miR-21-5p-mediated topoisomerase drug resistance in human colorectal cancer cells . Biomolecules .2019 ;(9):467

5. 2019 Wang PW,Lin TY,Hung YC,Chang WN,Yang PM,Chen MH, Yeh CT, Pan TL. Characterization of fibrinogen as a key modulator in patients with Wilson's diseases with functional proteomic tools . International Journal of Molecular Sciences .2019 ;(20):4528

6. 2019 Hsieh YY,Liu TP,Chou CJ,Chen HY,Lee KH,Yang PM. Integration of bioinformatics resources reveals the therapeutic benefits of gemcitabine and cell cycle intervention in SMAD4-deleted pancreatic ductal adenocarcinoma . Genes (Basel) .2019 ;(10):766

7. 2019 Leung SW,Chou CJ,Huang TC,Yang PM. An integrated bioinformatics analysis repurposes an antihelminthic drug niclosamide for treating HMGA2-overexpressing human colorectal cancer . Cancers (Basel) .2019 ;(11):1482

8. 2019 Yang PM,Hong YH,Hsu KC,Liu TP. p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma . American Journal of Cancer Research .2019 ;(9):2120-2139

9. 2019 Huang YM,Cheng CH,Pan SL,Yang PM,Lin DY,Lee KH. Gene expression signature-based approach identifies antifungal drug ciclopirox as a novel inhibitor of HMGA2 in colorectal cancer. . Biomolecules .2019 ;(9):688

10. 2019 Chen GW,Chen TY,Yang PM. Differential effect of herbal tea extracts on free fatty acids-, ethanol- and acetaminophen-induced hepatotoxicity in FL83B hepatocytes . Drug and Chemical Toxicology .2019

11. 2019 Wang PW,Hung YC,Lin TY,Fang JY,Yang PM,Chen MH, Pan TL. Comparison of the biological impact of UVA and UVB upon the skin with functional proteomics and immunohistochemistry. . Antioxidants .2019 ;(8):E569

12. 2018 Cheng YW ,Chou CJ ,Yang PM . Ten-eleven translocation 1 (TET1) gene is a potential target of miR-21-5p in human colorectal cancer . Surgical Oncology .2018 ;(27):76-81

13. 2018 Liu TP,Hsieh YY,Chou CJ,Yang PM. Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining . Royal Society Open Science .2018 ;(5):181321-181321

14. 2017 Liu TP,Hong YH,Yang PM. In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells . Oncotarget .2017 ;(8):86168-86180

15. 2017 Yang PM,Du JL,Chia JS,Wang GN,Hsu WB,Pu PC, Sun A, Chiang CP, Wang WB. The Chinese Herbal Mixture Tien-Hsien Liquid Augments the Anticancer Immunity in Tumor Cell-Vaccinated Mice . Integrative Cancer Therapies .2017 ;(16):319-328

16. 2017 Yang PM,Hung CF. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma . Oncotarget .2017 ;(8):46145-46162

17. 2016 Hsieh YY,Lo HL,Yang PM. EZH2 inhibitors transcriptionally upregulate cytotoxic autophagy and cytoprotective unfolded protein response in human colorectal cancer cells . American Journal of Cancer Research .2016 ;(6):1661-1680

18. 2016 Liu TP,Hong YH,Tung KY,Yang PM. In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes. . Oncoscience .2016 ;(3):9-20

19. 2016 Kao CY,Yang PM,Wu MH,Huang CC,Lee YC,Lee KH. Heat shock protein 90 is involved in the regulation of HMGA2-driven growth and epithelial-to-mesenchymal transition of colorectal cancer cells . PeerJ .2016 ;(4):e1683-e1683

20. 2016 Hsieh YY,Huang TC,Lo HL,Jhan JY,Chen ST,Yang PM. Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine . Oncotarget .2016 ;(7):1-16

21. 2016 Hsieh YY,Chou CJ,Lo HL,Yang PM. Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer . Cell Death Discovery .2016

22. 2015 Liu CH,Tang WC,Sia P,Huang CC,Yang PM,Wu MH, Lai IL, Lee KH. Berberine Inhibits the Metastatic Ability of Prostate Cancer Cells by Suppressing Epithelial-to-Mesenchymal Transition (EMT)-Associated Genes with Predictive and Prognostic Relevance. . International Journal of Medical Sciences .2015 ;(12):63-71

23. 2015 Liu TP,Yang PM. Autophagic effect of SAM-competitive EZH2 inhibitors on cancer cells. . Cancer Cell & Microenvironment (Research Highlight) .2015 ;(2):e551-e551

24. 2015 Nana AW,Yang PM,Lin HY. Overview of transforming growth factor β superfamily involvement in glioblastoma initiation and progression. . Asian Pacific Journal of Cancer Prevention .2015 ;(16):6813-6823

25. 2015 Liu TP,Lo HL,Wei LS,Hsiao HH,Yang PM. S-adenosyl methionine (SAM)-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells . Anti-Cancer Drugs .2015 ;(26):139-147

26. 2014 Lee KH,Lo HL,Tang WC,Hsiao HH,Yang PM. A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine . Scientific Reports .2014 ;(4):6394-6394

27. 2014 Huang YH#,Yang PM#,Chuah QY,Lee YJ,Hsieh YF,Peng CW, Chiu SJ (#Equal contribution). Autophagy promotes radiation-induced senescence but inhibits bystander effects in human breast cancer cells . Autophagy .2014 ;(10):1212-1228

28. 2014 Tsai CT,Yang PM,Chern TR,Chuang SH,Lin JH,Klemm L, Müschen M, Chen CC. AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine . Oncotarget .2014 ;(5):211-223

29. 2014 Liao EC,Hsu YT,Chuah QY,Lee YJ,Hu JY,Huang TC, Yang PM*, Chiu SJ*. Radiation induces senescence and a bystander effect through metabolic alterations . Cell Death & Disease .2014 ;(5):e1255-e1255

30. 2013 Yu YC#,Yang PM#,Chuah QY,Huang YH,Peng CW,Lee YJ, Chiu SJ (#Equal contribution). Radiation-induced senescence in securin-deficient cancer cells promotes cell invasion involving the IL-6/STAT3 and PDGF-BB/PDGFR pathways . Scientific Reports .2013 ;(3):1675-1675

31. 2013 Yang PM#,Lin YT#,Shun CT,Lin SH,Wei TT,Chuang SH, Wu MS, Chen CC(#Equal contribution). Zebularine inhibits tumorigenesis and stemness of colorectal cancer via p53-dependent endoplasmic reticulum stress. . Scientific Reports .2013 ;(3):3219-3219

32. 2013 Yu PH,Chou SF,Chen CL,Hung H,Lai CY,Yang PM, Jeng YM, Liaw SF, Kuo HH, Hsu HC, Chen JY, Wang WB. Upregulation of endocan by epstein-barr virus latent membrane protein 1 and its clinical significance in nasopharyngeal carcinoma. . PLoS One .2013 ;(8):e82254-e82254

33. 2012 Yang PM,Lin PJ,Chen CC. CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1 . Epigenetics .2012 ;(7):390-399

34. 2012 Tseng HH,Chuah QY,Yang PM,Chen CT,Chao JC,Lin MD, Chiu SJ. Securin enhances the anti-cancer effects of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075) in human colorectal cancer cells . PLoS One .2012 ;(7):e36006-e36006

35. 2012 Yang PM,Tseng HH,Peng CW,Chen WS,Chiu SJ. Dietary flavonoid fisetin targets caspase-3-deficient human breast cancer MCF-7 cells by induction of caspase-7-associated apoptosis and inhibition of autophagy . International Journal of Oncology .2012 ;(40):469-478

36. 2011 Yu SH,Yang PM,Peng CW,Yu YC,Chiu SJ. Securin depletion sensitizes human colon cancer cells to fisetin-induced apoptosis . Cancer Letters .2011 ;(300):96-104

37. 2011 Huang WY,Yang PM,Chang YF,Marquez VE,Chen CC. Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2 . Biochemical Pharmacology .2011 ;(81):510-517

38. 2011 Yang PM,Chen CC. Life or death? Autophagy in anticancer therapies with statins and histone deacetylase inhibitors . Autophagy (Research Highlight) .2011 ;(7):107-108

39. 2010 Yang PM#,Huang WC#,Lin YC#,Huang WY,Wu HA,Chen WL, Chang YF, Chou CW, Tzeng CC, Chen YL, Chen CC (#Equal contribution). Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis . Journal of Cellular and Molecular Medicine .2010 ;(14):687-698

40. 2010 Yang PM#,Liu YL#,Lin YC#,Shun CT,Wu MS,Chen CC (#Equal contribution). Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies . Cancer Research .2010 ;(70):7699-7709

41. 2010 Yang PM,Lin JH,Huang WY,Lin YC,Yeh SH,Chen CC. Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate . Biochemical and Biophysical Research Communications .2010 ;(391):1396-1399

42. 2010 Liu YL#,Yang PM#,Shun CT,Wu MS,Weng JR,Chen CC (#Equal contribution). Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma . Autophagy .2010 ;(6):1057-1065

43. 2009 Hsu TS#,Yang PM#,Tsai JS,Lin LY,(#Equal contribution). Attenuation of cadmium-induced necrotic cell death by necrostatin-1: potential necrostatin-1 acting sites . Toxicology and Applied Pharmacology .2009 ;(235):153-162

44. 2009 Lin MH,Hsu TS,Yang PM,Tsai MY,Perng TP,Lin LY. Comparison of organic and inorganic germanium compounds in cellular radiosensitivity and preparation of germanium nanoparticles as a radiosensitizer . International Journal of Radiation Biology .2009 ;(85):214-226

45. 2007 Yang PM,Chen HC,Tsai JS,Lin LY. Cadmium induces Ca2+-dependent necrotic cell death through calpain-triggered mitochondrial depolarization and reactive oxygen species-mediated inhibition of nuclear factor-kappaB activity . Chemical Research in Toxicology .2007 ;(20):406-415

46. 2005 Yang PM,Chiu SJ,Lin LY. Differential effects of salen and manganese-salen complex (EUK-8) on the regulation of cellular cadmium uptake and toxicity . Toxicological Sciences .2005 ;(85):551-559

47. 2004 Yang PM,Chiu SJ,Lin KA,Lin LY. Effect of cadmium on cell cycle progression in Chinese hamster ovary cells . Chemico-Biological Interactions .2004 ;(149):125-136

研究計畫

計畫名稱
108 透過老藥新用策略來開發以Stathmin 1為標靶之抗肝癌新藥
補助單位
阮綜合醫療社團法人阮綜合醫院

計畫名稱
106 探討耐克螺對HMGA2高表現大腸直腸癌之抗癌作用
補助單位
阮綜合醫療社團法人阮綜合醫院

計畫名稱
106 以肝細胞體外模式探討花草茶萃取物改善非酒精性脂肪肝炎之療效(花草茶萃取物之保健功效研究)
補助單位
臺北醫學大學

計畫名稱
105 不同APC基因狀態大腸直腸癌患者藥物治療之抗藥性機轉研究-探討miR-21調控大腸直腸癌細胞TET1/5-hydroxymethylcytosine表現對其化療反應之關聯(3/3)
補助單位

計畫名稱
104 The role of miR-21 in cancer stemness and anoikis resistance of colorectal cancer cells.
補助單位
科技部

計畫名稱
104 不同APC基因狀態大腸直腸癌患者藥物治療之抗藥性機轉研究-探討miR-21調控大腸直腸癌細胞TET1/5-hydroxymethylcytosine表現對其化療反應之關聯(2/3)
補助單位
科技部

計畫名稱
104 探討miR-21調控大腸直腸癌細胞 TET1/5- hydroxymethylcytosine表現對其化療反應之關聯(2/3)(相對補助)
補助單位
臺北醫學大學

計畫名稱
103 運用化學基因體學方法開發新穎核糖核苷酸還原酶抑制劑用以治療大腸直腸癌
補助單位
衛生福利部雙和醫院(委託臺北醫學大學興建經營)

計畫名稱
103 探討細胞自噬受到表觀基因調控之機轉
補助單位
科技部

計畫名稱
103 不同APC基因狀態大腸直腸癌患者藥物治療之抗藥性機轉研究-探討miR-21調控大腸直腸癌細胞TET1/5-hydroxymethylcytosine表現對其化療反應之關聯(1/3)
補助單位
科技部

計畫名稱
103 探討miR-21調控大腸直腸癌細胞 TET1/5- hydroxymethylcytosine表現對其化療反應之關聯(1/3)(相對補助)
補助單位
臺北醫學大學

計畫名稱
102 探討EZH2抑制劑UNC1999誘導大腸直腸癌細胞自噬之機轉
補助單位
衛生福利部雙和醫院(委託臺北醫學大學興建經營)

計畫名稱
102 應用zebularine治療大腸直腸癌:以缺氧誘導分子(HIF-1α)為標靶(2-2)
補助單位
行政院國家科學委員會

計畫名稱
102 應用ZEBULARINE治療大腸直腸癌:以缺氧誘導分子(HIF-1Α)為標靶(2-2)
補助單位
科技部

計畫名稱
101 探討DNMT抑制劑治療大腸直腸癌之新機轉
補助單位
衛生福利部雙和醫院(委託臺北醫學大學興建經營)

計畫名稱
101 應用zebularine治療大腸直腸癌:以缺氧誘導分子(HIF-1α)為標靶(1-2)
補助單位
行政院國家科學委員會

計畫名稱
101 TMU101-AE1-B25
補助單位
學校